Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
Rhea-AI Summary
Kairos Pharma (NYSE American: KAPA) will present at the LD Micro Invitational XVI at the Luxe Sunset Boulevard Hotel in Los Angeles on Monday, May 18, 2026 at 1:00 PM PDT. CEO and Chairman Dr. John Yu will provide an update on the company’s clinical program and partnering activities.
The LD Micro Invitational XVI runs May 18–19, 2026, featuring micro and small-cap companies presenting in half-hour slots and meeting investors. A webcast link is indicated for Kairos Pharma’s presentation.
Positive
- None.
Negative
- None.
News Market Reaction – KAPA
In the May 13 session, KAPA declined 4.33%, reflecting a moderate negative market reaction. Argus tracked a peak move of +13.3% during that session. Argus tracked a trough of -4.4% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 08 | Going-concern update | Negative | -5.4% | Auditor highlights going-concern language in recent 10-K financial statements. |
| Apr 15 | Innovation award | Positive | +0.1% | Company recognized for ENV‑105-based resistance-modulating oncology approach. |
| Mar 02 | Asset acquisition | Positive | +0.7% | Binding deal for CL-273 pan‑EGFR inhibitor expanding NSCLC pipeline. |
| Feb 26 | Acquisition term sheet | Positive | -12.2% | Term sheet to acquire two NSCLC assets CL‑273 and CL‑741 from Celyn. |
| Jan 20 | Conference participation | Neutral | +0.3% | Investor conference presentation and one-on-one meeting availability announcement. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News and corporate developments have generally aligned with price moves, though one positive acquisition headline saw a sharp negative reaction.
Over the last few months, Kairos has balanced corporate and clinical updates with financing and governance steps. A Feb 26, 2026 acquisition term sheet for two NSCLC assets triggered a -12.15% move, while the binding CL-273 deal on Mar 2, 2026 saw a modest 0.74% gain. A going-concern reminder on May 8, 2026 coincided with a -5.36% drop. Earlier, a conference presentation on Jan 20, 2026 and an innovation award on Apr 15, 2026 had minimal but positive reactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Los Angeles, California--(Newsfile Corp. - May 13, 2026) - Kairos Pharma, Ltd. (NYSE American: KAPA) announced today that it will be participating in the 16th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, CA May 18th and 19th, 2026.
Kairos Pharma, Ltd. is scheduled to present on Monday, May 18, 2026 at 01:00 PM. John Yu CEO, will be presenting on behalf of the company.
Dr. John Yu, CEO and Chairman of Kairos Pharma will give an update on Kairos' clinical program and partnering activities.
Event: LD Micro Invitational XVI
Date: Monday, May 18, 2026
Time: 01:00 PM PDT
WEBCAST LINK
Summary of LD Micro Invitational XVI
- The 2026 LD Micro Invitational XVI will take place May 18th and 19th, 2026 at the Luxe Hotel Sunset Boulevard Hotel in Los Angeles.
- Registration will begin at 5:30 PM PT on May 17th in conjunction with a welcome reception.
- Presentations will take place from 9:00 AM PT - 5:00 PM PT on the 18th, followed by panels and keynote speakers.
- Presentations will take place from 9:00 AM PT - 5:00 PM PT on the 19th, followed by the LD Micro Moneyball Afterparty.
This two-day event will feature micro and small-cap companies across all sectors, presenting in half-hour increments, and attending private meetings with investors.
About Kairos Pharma, Ltd.
Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105-a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com.
About LD Micro
LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Through its dynamic, investor-driven conferences and curated company exposure, LD has served as an invaluable asset to all those interested in discovering the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.
To register, please contact: registration@ldmicro.com.
For further information on Kairos Pharma, Ltd. :
CoreIR
3102486693
investors@kairospharma.com
kairospharma.com